Open Access

Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome

  • Authors:
    • Changfu Cao
    • Meiqing Su
  • View Affiliations

  • Published online on: February 22, 2019     https://doi.org/10.3892/etm.2019.7295
  • Pages: 3009-3014
  • Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome were investigated. Eighty patients with metabolic syndrome treated in Linyi Central Hospital from January 2017 to December 2017 were selected and divided into control group (n=40) and observation group (n=40). Patients in control group were treated with regular therapy using the Western medicine and drugs, while those in observation group, based on the treatment in control group, were treated with berberine. Changes in relevant indexes to blood glucose and lipid metabolisms and inflammatory factors were compared between the two groups. The correlation of inflammatory factor with fasting blood glucose, insulin resistance, triglyceride and total cholesterol was analyzed. At 1 month after treatment, levels of fasting blood glucose, 2 h postprandial blood glucose, insulin resistance index and blood lipid indexes in both groups were lower than those at 1 week after treatment (P<0.05). At 1 month after treatment, levels of fasting blood glucose, 2 h postprandial blood glucose, insulin resistance index and blood lipid indexes in observation group were significantly lower than those in control group during the same period (P<0.05). Moreover, levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in both groups at 1 month after treatment were lower than those at 1 week after treatment (P<0.05), and they were lower in observation group at 1 month after treatment than those in control group during the same period (P<0.05). Finally, hs-CRP was positively correlated with fasting blood glucose, insulin resistance, total cholesterol and triglyceride. The combined application of berberine in patients with metabolic syndrome can effectively regulate blood glucose and blood lipid of patients, alleviate insulin resistance and reduce the level of inflammatory response in the body.

Introduction

Metabolic syndrome mainly refers to a group of pathophysiological changes based on insulin resistance (1), the major clinical manifestations are central obesity, increase in blood glucose, increase in blood lipid and increase in blood pressure, seriously affecting the physical health of patients. The above clinical manifestations of metabolic syndrome, as a metabolic dysfunction-related disease (2), have certain common risk factors, which are in line with the ‘concept of holism, homotherapy for heteropathy’ in the traditional Chinese medicine. It is of important significance to effectively intervene in patients with cardiovascular diseases, such as hypertension, and endocrine diseases (like type 2 diabetes mellitus) (3), alleviate or avoid the occurrence of insulin resistance and make full use of the concept of ‘preventive treatment of disease’, namely ‘prevention before disease onset, prevention of disease from exacerbating’, in the traditional Chinese medicine, thereby increasing the therapeutic effect on metabolic syndrome and improving the prognosis of patients (4).

Berberine, also known as Berberine hydrochloride in clinic, is the isoquinoline alkaloid, an active ingredient extracted from Chinese herbal medicines, such as Coptis chinensis and Phellodendron amurense, which has dominant advantages such as reducing blood glucose, and regulating blood lipid and vascular endothelial cells (5). In recent years, berberine has been widely used in the treatment of type 2 diabetes mellitus, hypertension and hyperlipidemia (6). With the deepening of fundamental research on berberine, it has been confirmed that the main mechanisms of berberine in reducing blood glucose and blood pressure and regulating blood lipid are promotion of insulin secretion and improvement of the body's insulin resistance (7). To better investigate the clinical value of berberine in the treatment of metabolic syndrome, this study was performed from the perspectives of blood glucose, blood lipid, insulin resistance and inflammatory factor levels.

Patients and methods

Patient data

A total of 80 patients with metabolic syndrome treated in Linyi Central Hospital (Linyi, China) from January 2017 to December 2017 were selected. All patients met the diagnostic criteria of the Chinese Medical Association (8) for type 2 diabetes mellitus, hyperlipidemia and hypertension. Before enrollment, patients signed an informed consent, and this study was approved by the Ethics Committee of Linyi Central Hospital. Patients enrolled were aged 60–80 years, and they were physically healthy in the past. Exclusion criteria: i) Patients complicated with other endocrine system diseases, mental diseases, malignant tumor or chronic obstructive pulmonary disease, ii) patients who were illiterate, allergic to drugs applied or could not pay the medical expenses. Patients were divided into two groups with 40 cases in each group using the random number method. There were no statistically significant differences in comparisons of general data and related indexes between the two groups (P>0.05) (Table I).

Table I.

Comparison of general data and related indexes between the two groups (mean ± SD).

Table I.

Comparison of general data and related indexes between the two groups (mean ± SD).

GroupSex (male/female)Age (years)Fasting blood glucose (mmol/l)2 h postprandial blood glucose (mmol/l)Insulin resistance
Observation group20/2065.6±1.810.5±0.613.5±1.31.5±0.1
Control group20/2065.5±1.810.6±0.613.6±1.31.5±0.1
χ2 or t value<0.0010.2480.7450.344<0.001
P-value>0.050.8040.4580.732>0.05

Continued

GroupTriglyceride (mmol/l)Total cholesterol (mmol/l)Interleukin-6 (IL-6) (ng/l)Tumor necrosis factor-α (TNF-α) (ng/l)High-sensitivity C-reactive protein (hs-CRP) (ml/l)

Observation group2.53±0.136.11±0.090.69±0.05253.1±2.125.6±1.3
Control group2.55±0.136.12±0.100.70±0.05253.6±2.025.7±1.4
χ2 or t value0.6880.4700.8941.0900.331
P-value0.4930.6400.3740.2790.742
Methods

Patients in control group were treated with regular therapy using the Western medicine and drugs strictly in accordance with the treatment guidelines of metabolic syndrome of the Chinese Medical Association. First of all, the weight of patients was reduced, the diet adjustment was strengthened, and the body mass index ≤28. Patients exercised properly according to the body's tolerance, and it was recommended that they take part in light-moderate physical activity every day for half an hour. In addition, the insulin resistance was reduced, in other words, the blood glucose-regulating drugs, such as metformin and insulin sensitizing drug thiazolidinedione, were applied while diet and exercise interventions were performed. At the same time, the intervention in hyperlipidemia was also performed, and it was advised that fibrates and statins be applied. Finally, the patient's blood pressure was adjusted and controlled within 130/80 mmHg. In terms of antihypertensive drugs, angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin II receptor antagonist (ARB) were preferred choices. Patients in observation group, based on the treatment in control group, were treated with berberine (Jiangxi Sinopharm Co., Ltd., Jiangxi, China, NMPN Z36020766) 3 times a day (4 tablets/time).

Observation indexes

All patients were followed up for 1 month. Changes in relevant indexes to blood glucose and lipid metabolisms and inflammatory factors were compared between the two groups at 1 week and 1 month after treatment. The correlations of inflammatory factor hs-CRP with fasting blood glucose, insulin resistance, triglyceride and total cholesterol were analyzed.

Evaluation criteria

Related detection indexes to blood glucose included fasting blood glucose (3.9–6.1 mmol/l), 2 h postprandial blood glucose (≤7.8 mmol/l) and homeostasis model assessment - insulin resistance (HOMA-IR) [reference value: 1, calculation formula: fasting blood glucose (mmol/l) × fasting insulin (mU/l)]. Related indexes to blood lipid included triglyceride (0.56–1.71 mmol/l) and total cholesterol (2.83–5.17 mmol/l). Inflammation-related factors included hs-CRP (<10 ml/l), IL-6 (0.37–0.46 ng/l) and TNF-α (5–100 ng/l).

Statistical analysis

SPSS 13.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Measurement data are presented as mean ± standard deviation (mean ±SD). Student's t-test was used for the comparison of related indexes to blood glucose and lipid metabolisms between the two groups at different observation points, the Chi-square test (χ2) was used for the comparison of adverse reactions between the two groups, and correlations of hs-CRP with fasting blood glucose, insulin resistance, total cholesterol and triglyceride were analyzed using the Pearson's correlation coefficient method. The procedure was repeated 3 times. P<0.05 was considered to indicate a statistically significant difference.

Results

Changes in related indexes to blood glucose and lipid metabolisms in both groups at 1 week and 1 month after treatment

At 1 month after treatment, levels of fasting blood glucose, 2 h postprandial blood glucose and insulin resistance index in both groups were lower than those at 1 week after treatment (P<0.05), and levels of blood lipid indexes (triglyceride and total cholesterol) were also lower than those at 1 week after treatment (P<0.05). At 1 month after treatment, levels of fasting blood glucose, 2 h postprandial blood glucose and insulin resistance index in observation group were significantly decreased compared with those in control group during the same period (P<0.05), and levels of blood lipid indexes (triglyceride and total cholesterol) were also lowered compared with those in control group during the same period (P<0.05) (Table II).

Table II.

Changes in related indexes to blood glucose and lipid metabolisms in both groups at 1 week and 1 month after treatment (mean ± SD).

Table II.

Changes in related indexes to blood glucose and lipid metabolisms in both groups at 1 week and 1 month after treatment (mean ± SD).

GroupTreatmentFasting blood glucose (mmol/l)2 h postprandial blood glucose (mmol/l)Insulin resistanceTriglyceride (mmol/l)Total cholesterol (mmol/l)
Observation group1 week after treatment7.9±0.39.9±0.51.3±0.12.12±0.085.39±0.15
1 month after treatment5.6±0.2a,b7.5±0.3a,b1.1±0.11a,b 1.56±0.07a,b 3.69±0.08a,b
Control group1 week after treatment8.0±0.410.0±0.51.4±0.12.13±0.095.40±0.16
1 month after treatment6.5±0.3a8.5±0.61a1.3±0.11a 1.96±0.061a 5.23±0.101a
t140.34526.0328.94433.31862.129
p1<0.001<0.001<0.001<0.001<0.001
t218.97412.1474.4729.9405.698
p2<0.001<0.001<0.001<0.001<0.001
t315.7879.4288.94427.44076.055
p3<0.001<0.001<0.001<0.001<0.001

a P<0.05 vs. observation group and control group at 1 week after treatment

b P<0.05 vs. control group at 1 week after treatment. t1, the results of comparison in observation group between 1 month after treatment and 1 week after treatment. t2, the results of comparison in observation group between 1 month after treatment and 1 week after treatment. t3, the results of comparison between observation group and control group at 1 month after treatment.

Changes in inflammatory factors in both groups at 1 week and 1 month after treatment

Levels of hs-CRP, IL-6 and TNF-α in both groups at 1 month after treatment were lower than those at 1 week after treatment (P<0.05), and they were lower in observation group at 1 month after treatment than those in control group during the same period (P<0.05) (Table III).

Table III.

Changes in inflammatory factors in both groups at 1 week and 1 month after treatment (mean ± SD).

Table III.

Changes in inflammatory factors in both groups at 1 week and 1 month after treatment (mean ± SD).

GroupTreatmenths-CRP (ml/l)IL-6 (ng/l)TNF-α (ng/l)
Observation group1 week after treatment12.3±0.50.59±0.06136.8±11.1
1 month after treatment 8.5±0.3a,b 0.43±0.04a,b 83.2±7.6a,b
Control group1 week after treatment14.6±0.60.68±0.06146.5±11.3
1 month after treatment 11.6±0.4a 0.51±0.05a 108.9±8.3a
t141.21714.03325.199
p1<0.001<0.001<0.001
t226.31213.76616.961
p2<0.001<0.001<0.001
t339.2127.90214.443
p3<0.001<0.001<0.001

a P<0.05 vs. observation group and control group at 1 week after treatment

b P<0.05 vs. control group at 1 week after treatment. t1, the results of comparison in observation group between 1 month after treatment and 1 week after treatment. t2, the results of comparison in observation group between 1 month after treatment and 1 week after treatment. t3, the results of comparison between observation group and control group at 1 month after treatment.

Correlation analysis of inflammatory factor hs-CRP with fasting blood glucose

There was a positive correlation between inflammatory factor hs-CRP and fasting blood glucose (r=0.9242, P<0.05) (Fig. 1).

Correlation analysis of inflammatory factor hs-CRP with insulin resistance

There was a positive correlation between inflammatory factor hs-CRP and insulin resistance (r=0.9929, P<0.05) (Fig. 2).

Correlation analysis of inflammatory factor hs-CRP with triglyceride

There was a positive correlation between inflammatory factor hs-CRP and triglyceride (r=0.9235, P<0.05) (Fig. 3).

Correlation analysis of inflammatory factor hs-CRP with total cholesterol

There was a positive correlation between inflammatory factor hs-CRP and total cholesterol (r=0.9665, P<0.05) (Fig. 4).

Comparison of adverse reactions between the two groups

There was no statistically significant difference in the overall incidence rate of adverse reactions, such as ketoacidosis, hyperglycemic coma, hypoglycemia and nausea and vomiting, between the two groups (P>0.05) (Table IV).

Table IV.

Comparison of adverse reactions between the two groups.

Table IV.

Comparison of adverse reactions between the two groups.

GroupKetoacidosisHyperglycemic comaHypoglycemiaNausea and vomitingOverall incidence rate
Observation group11114 (10.0%)
Control group12104 (10.0%)
χ2 value <0.001
P-value <0.05

Discussion

Metabolic syndrome is a group of clinical syndromes determined by heredity, environment, living habits and other factors, whose main mechanism is insulin resistance (9). Patients have symptoms including central obesity, atherosclerosis, rise of blood lipid, pathoglycemia and elevation of blood pressure, which may be accompanied by microalbuminuria, hyperuricemia and long-term rise of chronic inflammatory cytokines (10). Currently, most scholars consider that insulin resistance is the most crucial independent risk factor and central link that lead to metabolic syndrome (11). Treatment for metabolic syndrome is based on improvement of patients' way of life, regulation of eating habits, exercise training and loss of weight, combined with drug therapy of reducing blood lipid and regulating blood pressure and blood glucose (12). Berberine can regulate various metabolic disorders of metabolic syndrome, which has advantages of wide medicinal herbs resources, low price, smaller adverse reactions, and is also safe and convenient (13).

In this study, patients with metabolic syndrome in control group were given regular Western medicine treatment strictly following guideline requirements, while those in observation group received berberine treatment on the basis of that in control group. By analyzing changes of related indexes to blood glucose and lipid metabolisms in the groups at 1 week and 1 month after treatment, it was found that related indexes to blood glucose and lipid in both groups were improved at 1 month after treatment, but levels of fasting blood glucose, 2 h postprandial blood glucose and insulin resistance index in observation group were significantly lower than those in control group at 1 month after treatment, and levels of blood lipid indexes (triglyceride and total cholesterol) in observation group were lower than those in control group at 1 month after treatment, indicating that combined use of berberine can regulate blood glucose and blood lipid levels more effectively and lighten insulin resistance. By exploring changes in relevant indexes of inflammatory factors in both groups at 1 week and 1 month after treatment, it was found that hs-CRP, IL-6 and TNF-α levels in both groups were also lower than those at 1 week after treatment, but hs-CRP, IL-6 and TNF-α levels in observation group were all lower than those in control group at 1 month after treatment, indicating that combined use of berberine tablets is of important significance for reducing inflammatory reaction in patients with metabolic syndrome. From the correlation research on inflammatory response factor hs-CRP with fasting blood glucose, insulin resistance, total cholesterol and triglyceride, it was revealed that hs-CRP was positively related to fasting blood glucose, insulin resistance, total cholesterol and triglyceride, which further indicates that there is chronic inflammatory response in the body of patients with metabolic syndrome and the severity degree of inflammatory response is related to blood glucose and blood lipid metabolism. Chronic inflammatory response may also lead to increase of insulin resistance in the body and further worsen the disease condition. Besides, combined use of berberine tablets did not increase the incidence of adverse reactions of treatment, so combined use of berberine tablets is of high safety.

In this study, combined use of berberine could effectively improve activity of adenosine monophosphate-activated protein kinase (AMPK) of islet cells, thus promoting activation of cyclic adenosine monophosphate (CAMP) signal pathway (14) and active secretion of insulin in the body. Moreover, berberine can also stimulate free fatty acid to induce secretion of insulin (15). Berberine improves physiological stimulation of glucose via cascade reaction of insulin-like growth factor-1 (IGF-1), thus inducing secretion of insulin in the body, reducing insulin resistance, and improving sensitivity of liver, muscle tissues and fat to insulin (16). Berberine can improve the activity and promote the proliferation of insulin β cells (17). Therefore, the combined use of berberine in observation group could better control fasting blood glucose and 2 h postprandial plasma glucose and reduce insulin resistance in the body. Berberine inhibits synthesis and secretion of proteolipid protein and activity of peroxisome by enhancing low density lipoprotein receptor level and promoting adenylate-phosphoric acid-activated protein kinase activity, thus regulating blood lipid and inhibiting proliferation and differentiation of adipocytes, so as to achieve the objective of reducing free fatty acid in serum (18,19). Consequently, triglyceride and total cholesterol decreased significantly after combined use of berberine in observation group. In addition, berberine can also evidently decrease levels of hs-CRP, IL-6, TNF-α and other inflammatory cytokines in the body (20), improve calcium overload and ischemia reperfusion injury and provide anti-oxidative capacity (21).

In conclusion, combined use of berberine for patients with metabolic syndrome can effectively regulate blood glucose and lipid, lighten insulin resistance in the body and reduce inflammatory response level.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

CC wrote the manuscript and collected the general data. CC and MS analyzed the relevant indexes to blood glucose and lipid metabolisms and inflammatory factors. Both authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Linyi Central Hospital (Linyi, China) and informed consents were signed by the patients or the guardians.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Saleem F and Rizvi SW: New therapeutic approaches in obesity and metabolic syndrome associated with polycystic ovary syndrome. Cureus. 9:e18442017.PubMed/NCBI

2 

Marchitto N, Sindona F, Fabrizio A, Mauti M, Andreozzi S, Dalmaso S and Raimondi G: Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome. Minerva Cardioangiol. 66:124–125. 2018.PubMed/NCBI

3 

Liu Q, Zhu L, Cheng C, Hu YY and Feng Q: Natural active compounds from plant food and chinese herbal medicine for nonalcoholic fatty liver disease. Curr Pharm Des. 23:5136–5162. 2017.PubMed/NCBI

4 

Dahlberg CJ, Ou JJ, Babish JG, Lamb JJ, Eliason S, Brabazon H, Gao W, Kaadige MR and Tripp ML: A 13-week low glycemic load diet and lifestyle modification program combining low glycemic load protein shakes and targeted nutraceuticals improved weight loss and cardio-metabolic risk factors. Can J Physiol Pharmacol. 95:1414–1425. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Sirtori CR, Pavanello C, Calabresi L and Ruscica M: Nutraceutical approaches to metabolic syndrome. Ann Med. 49:678–697. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G and Gentile S: Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: A 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J Biol Regul Homeost Agents. 31:495–502. 2017.PubMed/NCBI

7 

Tabeshpour J, Imenshahidi M and Hosseinzadeh H: A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci. 20:557–568. 2017.PubMed/NCBI

8 

Ong M, Peng J, Jin X and Qu X: Chinese herbal medicine for the optimal management of polycystic ovary syndrome. Am J Chin Med. 45:405–422. 2017. View Article : Google Scholar : PubMed/NCBI

9 

Lu YH, Lu JM, Wang SY, Li CL, Liu LS, Zheng RP, Tian H, Wang XL, Yang LJ, Zhang YQ and Pan CY: Comparison of the diagnostic criteria of metabolic syndrome by International Diabetes Federation and that by Chinese Medical Association Diabetes Branch. Zhonghua Yi Xue Za Zhi. 86:386–389. 2006.(In Chinese). PubMed/NCBI

10 

Zhao L, Cang Z, Sun H, Nie X, Wang N and Lu Y: Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord. 17:132017. View Article : Google Scholar : PubMed/NCBI

11 

Choi YJ, Lee KY, Jung SH, Kim HS, Shim G, Kim MG, Oh YK, Oh SH, Jun DW and Lee BH: Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. Toxicol Appl Pharmacol. 316:74–82. 2017. View Article : Google Scholar : PubMed/NCBI

12 

Chow YL, Sogame M and Sato F: 13-Methylberberine, a berberine analogue with stronger anti-adipogenic effects on mouse 3T3-L1 cells. Sci Rep. 6:381292016. View Article : Google Scholar : PubMed/NCBI

13 

He Q, Mei D, Sha S, Fan S, Wang L and Dong M: ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis. J Mol Endocrinol. 57:251–260. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Li M, Shu X, Xu H, Zhang C, Yang L, Zhang L and Ji G: Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. J Transl Med. 14:2372016. View Article : Google Scholar : PubMed/NCBI

15 

Millán J, Cicero AF, Torres F and Anguera A: Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. Clin Investig Arterioscler. 28:178–187. 2016.PubMed/NCBI

16 

Martínez-Abundis E, Méndez-Del Villar M, Pérez-Rubio KG, Zuñiga LY, Cortez-Navarrete M, Ramírez-Rodriguez A and González-Ortiz M: Novel nutraceutic therapies for the treatment of metabolic syndrome. World J Diabetes. 7:142–152. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Caliceti C, Franco P, Spinozzi S, Roda A and Cicero AF: Berberine: New insights from pharmacological aspects to clinical evidences in the management of metabolic disorders. Curr Med Chem. 23:1460–1476. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Patel S: Functional food red yeast rice (RYR) for metabolic syndrome amelioration: A review on pros and cons. World J Microbiol Biotechnol. 32:872016. View Article : Google Scholar : PubMed/NCBI

19 

Geng FH, Li GH, Zhang X, Zhang P, Dong MQ, Zhao ZJ, Zhang Y, Dong L and Gao F: Berberine improves mesenteric artery insulin sensitivity through up-regulating insulin receptor-mediated signalling in diabetic rats. Br J Pharmacol. 173:1569–1579. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Oikawa N, Nobushi Y, Wada T, Sonoda K, Okazaki Y, Tsutsumi S, Park YK, Kurokawa M, Shimba S and Yasukawa K: Inhibitory effects of compounds isolated from the dried branches and leaves of murta (Myrceugenia euosma) on lipid accumulation in 3T3-L1 cells. J Nat Med. 70:502–509. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Cicero AF and Colletti A: Role of phytochemicals in the management of metabolic syndrome. Phytomedicine. 23:1134–1144. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April-2019
Volume 17 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cao C and Su M: Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med 17: 3009-3014, 2019.
APA
Cao, C., & Su, M. (2019). Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Experimental and Therapeutic Medicine, 17, 3009-3014. https://doi.org/10.3892/etm.2019.7295
MLA
Cao, C., Su, M."Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome". Experimental and Therapeutic Medicine 17.4 (2019): 3009-3014.
Chicago
Cao, C., Su, M."Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome". Experimental and Therapeutic Medicine 17, no. 4 (2019): 3009-3014. https://doi.org/10.3892/etm.2019.7295